结直肠癌中的HER2向疗法:当前的情况和未来的方向
Na Chen1, Ling He2, Qiang Zou3
1State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, Sichuan, 610041, China; Center of Science and Research, Chengdu Medical College, Chengdu, 610500, China.
人类表皮生长因子受体2 (HER2) 是转移性结直肠癌 (CRC) 的目标. 针对性疗法对HER2阳性CRC有希望,但评估和抵抗机制需要进一步研究.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 结肠直肠癌 (CRC) 仍然是全球癌症死亡的主要原因,转移性疾病的预后不佳.
- 人类表皮生长因子受体2 (HER2) 是一种瘤原体驱动器,在其他癌症中被成功向.
- 大约5%的CRC患者表现出HER2突变或放大,呈现出治疗点.
研究的目的:
- 审查HER2在结直肠癌中的作用,作为瘤驱动因素,生物标志物和治疗点.
- 总结目前对转移性CRC的抗HER2疗法的临床应用所取得的进展和挑战.
- 突出需要标准化HER2评估和对抗性机制的研究.
主要方法:
- 本综述综合了关于HER2在结直肠癌中的现有文献.
- 它研究了针对HER2的药物的临床批准和应用.
- 该评论讨论了诊断评估方法和已知的耐药性机制.
主要成果:
- 特拉斯图祖马布和珀图祖马布,结合化疗,已被批准用于HER2阳性转移性CRC.
- 这种向疗法代表了对CRC患者的一个子集的重大进展.
- 对HER2评估的标准化和对抗药性机制的理解是关键的未满足需求.
结论:
- 在转移性结直肠癌患者的一个子集中,HER2是临床可行的标.
- 进一步的研究对于优化抗HER2疗法和克服耐药性至关重要.
- 需要标准化诊断方法,以确保适当的患者选择有针对性的治疗.
更多相关视频
08:29Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Mitogens and the Cell Cycle
